Literature DB >> 29143566

Electromyographic evaluation in children orthodontically treated for skeletal Class II malocclusion: Comparison of two treatment techniques.

Eleonora Ortu1, Davide Pietropaoli1, Fray Adib2, Chiara Masci1, Mario Giannoni1, Annalisa Monaco1.   

Abstract

OBJECTIVE: To compare the clinical efficacy of two techniques for fabricating a Bimler device by assessing the patient's surface electromyography (sEMG) activity at rest before treatment and six months after treatment.
METHODS: Twenty-four patients undergoing orthodontic treatment were enrolled in the study; 12 formed the test group and wore a Bimler device fabricated with a Myoprint impression using neuromuscular orthodontic technique and 12 formed the control group and were treated by traditional orthodontic technique with a wax bite in protrusion. The "rest" sEMG of each patient was recorded prior to treatment and six months after treatment.
RESULTS: The neuromuscular-designed Bimler device was more comfortable and provided better treatment results than the traditional Bimler device.
CONCLUSION: This study suggests that the patient group subjected to neuromuscular orthodontic treatment had a treatment outcome with more relaxed masticatory muscles and better function versus the traditional orthodontic treatment.

Entities:  

Keywords:  Class two skeletal; TENS; malocclusion; sEMG

Mesh:

Year:  2017        PMID: 29143566     DOI: 10.1080/08869634.2017.1393916

Source DB:  PubMed          Journal:  Cranio        ISSN: 0886-9634            Impact factor:   2.020


  2 in total

1.  A Device Improves Signs and Symptoms of TMD.

Authors:  Davide Pietropaoli; Barry C Cooper; Eleonora Ortu; Annalisa Monaco
Journal:  Pain Res Manag       Date:  2019-05-06       Impact factor: 3.037

2.  Standard Correction of Vision Worsens EMG Activity of Pericranial Muscles in Chronic TMD Subjects.

Authors:  Annalisa Monaco; Eleonora Ortu; Mario Giannoni; Pierdomenico D'Andrea; Ruggero Cattaneo; Alessandra Mummolo; Davide Pietropaoli
Journal:  Pain Res Manag       Date:  2020-04-13       Impact factor: 3.037

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.